An Open-Label, Single Dose Study to Investigate Striatal Dopamine D2 Receptor Binding of JNJ-37822681 Using [11C]Raclopride Positron Emission Tomography in Healthy Male Subjects

An Open-Label, Single Dose Study to Investigate Striatal Dopamine D2 Receptor Binding of JNJ-37822681 Using [11C]Raclopride Positron Emission Tomography in Healthy Male Subjects - PET study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON30989

Enrollment

Registered

2007-08-07

Start date

2007-09-15

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

Each subject will receive 2 dose levels of JNJ-37822681 and 3 [11C]raclopride PET scans.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: healthy male subjects between 18 - 55 years of age BMI between 18 and 30 kg/m²

Exclusion criteria

Exclusion criteria: History of, or currently active, significant illness or medical disorder Yearly cumulative dose due to exposure to radiation above 10 mSv Any significant MR abnormalities as determined by a neuroradiologist Metal implants Claustrophobia History of epilepsy or fits or unexplained black-outs Significant history of or current psychiatric or neurological disease

Design outcomes

Primary

Measure	Time frame
Dopamine D2 receptor binding is measured and the relation between the pharmacokintetics of JNJ-37822681 and the receptor binding is determined. safety and tolerability, adverse events, changes in blood pressure, pulse rate, lab. safety data, 12-lead ECG and physical examination and also studied.	—

Secondary

Measure	Time frame
n.a.p.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)